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Abstract
IMPORTANCE Chemotherapy during the first trimester of pregnancy should be avoided owing to
the risk of congenital malformations. However, the precise gestational age at which chemotherapy
can be initiated safely remains unclear.
OBJECTIVE To assess congenital malformation rates associated with gestational age at initiation of
chemotherapy among pregnant women with cancer.
DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study evaluated all pregnant
women who received chemotherapy between 1977 and 2019 registered in the International Network
on Cancer, Infertility and Pregnancy (INCIP) database. Data were analyzed from February 15 to June
2, 2020.
EXPOSURES Cancer treatment with chemotherapy during pregnancy.
MAIN OUTCOMES AND MEASURES Analysis was focused on major and minor structural
malformations in offspring, defined by EUROCAT, detected during pregnancy or at birth.
RESULTS A total of 755 women in the INCIP database who underwent cancer treatment with
chemotherapy during pregnancy were included in analysis. The median (range) age at cancer
diagnosis was 33 (14-48) years. Among offspring, the major congenital malformation rate was 3.6%
(95% CI, 2.4%-5.2%), and the minor congenital malformation rate was 1.9% (95% CI, 1.0%-3.1%).
Chemotherapy exposure prior to 12 weeks gestational age was associated with a high rate of major
congenital malformations, at 21.7% (95% CI, 7.5%-43.7%; odds ratio, 9.24 [95% CI, 3.13-27.30]).
When chemotherapy was initiated after gestational age 12 weeks, the frequency of major congenital
malformations was 3.0% (95% CI, 1.9%-4.6%), which was similar to the expected rates in the general
population. Minor malformations were comparable when exposure occurred before or after
gestational age 12 weeks (4.3% [95% CI, 0.1%-21.9%] vs 1.8% [95% CI, 1.0-3.0]; odds ratio, 3.13 [95%
CI, 0.39-25.28]). Of 29 women who received chemotherapy prior to 12 weeks gestation, 17 (58.6%)
were not aware of pregnancy, and 6 (20.7%) experienced a miscarriage (3 women [10.3%]) or
decided to terminate their pregnancy (3 women [10.3%]).
CONCLUSIONS AND RELEVANCE This cohort study found that chemotherapy was associated with
an increased risk of major congenital malformations only in the first 12 weeks of pregnancy. The risk
of congenital malformations when chemotherapy was administered during the first trimester and the
high number of incidental pregnancies during cancer treatment in the INCIP registry underscore the
importance of contraceptive advice and pregnancy testing at the start of chemotherapeutic
treatment in young women with cancer.
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Key Points
Question Is gestational age at initiation
of chemotherapy during pregnancy
associated with risk of congenital
malformations?
Findings In this cohort study including
755 pregnant women with cancer, the
risk of major congenital malformations
was elevated when first chemotherapy
exposure was prior to 12 weeks of
gestation, whereas the occurrence of
major congenital malformations was
similar to expected rates in the general
population when chemotherapy was
initiated after 12 weeks of gestation.
Meaning The findings of this study
could allow clinicians to better tailor
chemotherapy during pregnancy and to
inform patients on fetal risks of
malformations.
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2021;4(6):e2113180. doi:10.1001/jamanetworkopen.2021.13180 (Reprinted) June 9, 2021 1/9
Downloaded From: https://jamanetwork.com/ by a Radboud University Nijmegen User  on 08/06/2021
Introduction
Because chemotherapy attacks rapidly proliferating cells and is minimally selective, it also puts a
developing fetus at risk of teratogenic effects. Toxic events during the periconceptional period might
affect early embryogenesis and result in a miscarriage, whereas subsequent toxic exposure might
interfere with the formation of organs, with the most susceptible period occurring between 2 and 8
weeks after conception (between 4 and 10 weeks postmenstruation).1 There is a wide consensus that
chemotherapy should be administered until after organogenesis is completed, usually considered
the first trimester of pregnancy (ie, the first 13 weeks postmenstruation).1,2 However, the exact
timing of conception might be uncertain, and some systems (eg, eyes, genitals, hematopoietic
system, central nervous system) continue to develop after 10 weeks of gestation. Therefore, the
question remains in clinical practice: at what exact gestational age can chemotherapy be safely
initiated to avoid inducing congenital malformations?
To assess the immediate teratogenic role of prenatal chemotherapy, this cohort study evaluated
the presence of major and minor congenital malformations detected during pregnancy or at birth
among the offspring of patients registered in the International Network of Cancer, Infertility and
Pregnancy (INCIP).
Methods
The Ethical Committee of Unity Hospitals of Leuven, Belgium, approved data collection for this
cohort study. Prospectively registered patients provided written informed consent. Retrospectively
registered paitents were deidentified, so the need for informed consent was waived. This study
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline for cohort studies.
The INCIP registry contains retrospectively and prospectively collected oncological, obstetric,
and neonatal data, as well as offspring follow-up data of patients diagnosed with any pregnancy-
associated malignant neoplasm, reported by physicians with a special interest in cancer in young
women. Currently, there are 73 hospitals in 28 countries actively participating in INCIP. The registry
was started in 2005, and this cohort study was performed with a data cutoff of December 1, 2019.
Patient data, including gestational age at treatment initiation, duration of chemotherapy during
pregnancy, and obstetric and neonatal outcomes, were collected for all pregnant women who
received chemotherapy with known obstetric outcomes. Small for gestational age (SGA) was defined
as a birthweight less than the 10th percentile, and percentiles were corrected for gestational age,
sex, maternal height, maternal weight, ethnicity, and parity, according to the calculator from the
Gestation Network (version 8.0.4; Perinatal Institute). Preterm delivery was defined as birth before
37 weeks gestational age. Congenital malformations were defined as structural or chromosomal
malformations that were diagnosed prenatally or at birth. Classification in minor or major
malformations was performed based on the medical, functional, or cosmetic consequences,
according to EUROCAT guidelines.3
Statistical Analysis
We used descriptive analyses and observed the numbers of reported congenital malformations
according to gestational age at first chemotherapy exposure. The subgroup that initiated
chemotherapy before 12 weeks of pregnancy was reported separately, and we defined the odds ratio
(OR) and 95% CI for congenital malformations prior to 12 weeks of gestation. The χ2 test was used
to compare occurrence of malformations between the group exposed to chemotherapy prior to 12
weeks and the group with exposure after 12 weeks. P values were 2-sided, and P < .05 was
considered to indicate statistical significance for all analyses. Analyses were performed using SPSS
Statistics version 25.0 (IBM). Data were analyzed from February 15 to June 2, 2020.
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Results
In total, 755 pregnant women treated with chemotherapy between 1977 and 2019 were included in
analysis (Table 1). Median (range) maternal age at cancer diagnosis was 33 (14-48) years. Breast
cancer was the most common cancer type (451 women [59.8%]), and most pregnancies ended in a
live birth (745 women [99.4%]). A total of 27 neonates (3.6% [95% CI, 2.4%-5.2%]) were reported to
have major congenital malformations, and 14 neonates (1.9% [95% CI, 1.0%-3.1%]) had minor
congenital malformations. The occurrence of major congenital malformations was the highest if first
chemotherapy exposure was prior to 12 weeks gestational age, at 21.7% (95% CI, 7.5%-43.7%),
compared with 3.0% (95% CI, 1.9%-4.6%) congenital malformations among offspring of women
who began chemotherapy after 12 weeks gestation (OR, 9.24 [95% CI, 3.13-27.30]), with the greatest
risk for women who began chemotherapy periconceptionally (Figure and Table 2). The occurrence
of major malformations when chemotherapy was initiated after 12 weeks of gestation was lower and
remained stable with advanced pregnancy (Figure). The occurrence of minor malformations was
comparable with the rates expected in the general population when exposure occurred prior or after
12 weeks gestational age (4.3% [95% CI, 0.1%-21.9%] vs 1.8% [95% CI, 1.0-3.0]; OR, 3.13 [95% CI,
0.39-25.28).
A total of 29 women initiated chemotherapy prior to 12 weeks of gestation. In 17 women (58.6%),
pregnancy status was not known at the moment of chemotherapy initiation. A total of 6 patients
(20.7%, all with hematological malignant neoplasms) experienced an early miscarriage after chemo-
therapy (3 women [10.3%]) or opted to terminate the pregnancy for oncological reasons (3 women
[10.3%]). Of the remaining 23 neonates prenatally exposed to chemotherapy prior to 12 weeks of gesta-
tion, 6 (26.1%) had congenital malformations (Table 2). Notably, 2 children presented with very similar
symmetrical limb deformations following exposure to anthracycline-based treatment (ie, docetaxel,
doxorubicin; cyclophosphamide and 5-flourouracil, epirubicin, cyclophosphamide).
Discussion
This cohort study presents the largest and most detailed cohort on congenital malformation
occurrence according to gestational age at chemotherapy exposure, to our knowledge. We found an
association between chemotherapy before 12 weeks of gestation and increased risk of congenital
malformations detected during pregnancy or at birth. The overall congenital malformation rate
among offspring of mothers who initiated chemotherapy after 12 weeks of gestation was 4.8%,
which is comparable to the expected rates in the general population (ie, 2.5%-6.9% for major
malformations and 6.5%-35.8% for minor malformations).4-6 Furthermore, 23 patients (3.0%)
received chemotherapy without awareness of the pregnancy, underscoring the importance of
adequate anticonception counseling and pregnancy testing at the start of chemotherapeutic
treatment in young women with cancer.
To date, questions remain regarding when in the gestational period chemotherapy can be
initiated relatively safely. First-trimester chemotherapy exposure has been associated with 10% to
20% risk of major malformations.1 Mechanisms by which chemotherapeutics induce teratogenic
effects are incompletely understood. To date, the reported malformations after oncological
treatment during human pregnancy encompass all organ systems, without discernible pattern for
most cytotoxic drugs, except for aminopterin and methotrexate.1 The nature of teratogenesis is
extremely complex; individual genetic susceptibility, specific timing of cytotoxic exposure, and
specific type of (co-)medication all determine the spectrum of anomalies. Similar to this the findings
reported in this study, other studies have reported limb deformities after exposure to a combination
of cyclophosphamide and 5-fluorouracil in the first trimester of pregnancy.7,8 Most likely, this reflects
chemotherapy-related toxic effects in the time frame when digits develop (ie, 5 to 6 weeks of
gestation). However, proof of teratogenicity remains difficult because of other confounders, such as
multidrug use, maternal age, and genetic predisposition.
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Table 1. Clinical Characteristics of Patients
Characteristics
Patients, No. (%)
Total (n = 755)
Gestational age at chemotherapy exposure
<12 wk (n = 29) ≥12 wk (n = 726)









<30 175 (23.2) 9 (31.0) 116 (22.9)
30-35 344 (45.6) 15 (51.7) 328 (45.2)
>35 236 (31.3) 5 (17.2) 231 (31.8)
Cancer type
Breast 451 (59.7) 17 (58.6) 434 (59.8)
Cervical 59 (7.8) 0 59 (8.1)
Lymphoma 138 (18.3) 4 (13.8) 134 (18.5)
Leukemia 36 (4.8) 7 (24.1) 29 (4.0)
Ovarian 26 (3.4) 0 26 (3.6)
Gastrointestinal 27 (3.6) 0 27 (3.7)
Melanoma 1 (0.1) 0 1 (0.1)
Brain 3 (0.4) 1 (3.4) 2 (0.3)
Lung 4 (0.5) 0 4 (0.6)
Sarcoma 5 (0.7) 0 5 (0.7)
Other 5 (0.7) 0 5 (0.7)
Country of registration
Belgium 146 (19.3) 4 (13.8) 142 (19.5)
Czech Republic 28 (3.7) 0 28 (3.9)
Germany 7 (0.9) 0 7 (1)
Denmark 9 (1.2) 1 (3.4) 8 (1.1)
Spain 5 (0.7) 0 5 (0.7)
Italy 82 (10.9) 0 82 (11.3)
Mexico 19 (2.5) 2 (6.9) 17 (2.3)
The Netherlands 162 (21.5) 9 (31.0) 153 (21.1)
Russia 67 (8.9) 3 (10.3) 64 (8.8)
United States 197 (26.1) 9 (31.0) 188 (25.9)
Israel 7 (0.9) 0 7 (1.0)
Other 26 (3.4) 1 (3.4) 25 (3.4)
Timing of cancer diagnosis
Before pregnancy 14 (1.9) 7 (24.1) 7 (1.0)
First trimester 217 (28.7) 22 (75.9) 195 (26.9)
Second trimester 448 (59.3) 0 448 (61.7)
Third trimester 76 (10.1) 0 76 (10.5)
Pregnancy known at time of
chemotherapy initiation
No 23 (3.0) 17 (58.6) 6 (0.8)
Yes 732 (97.0) 12 (41.4) 720 (99.2)
Conception
Spontaneous 689 (92.5) 25 (86.2) 673 (92.7)
ART 57 (7.5) 4 (13.8) 53 (7.3)
Prior pregnancies
No 291 (38.5) 10 (34.5) 281 (38.7)
Yes 439 (58.1) 16 (55.2) 423 (58.3)
Not reported 25 (3.3) 3 (10.3) 22 (3.0)
Radiation therapy during pregnancy
(first trimester)
18 (2.4) 1 (3.4) 17 (2.3)
Surgery during pregnancy
(first trimester)
315 (41.7) 12 (41.4) 303 (41.7)
(continued)
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Table 1. Clinical Characteristics of Patients (continued)
Characteristics
Patients, No. (%)
Total (n = 755)
Gestational age at chemotherapy exposure
<12 wk (n = 29) ≥12 wk (n = 726)
Chemotherapy regimen
during pregnancy
ABVD 73 (9.7) 1 (3.4) 72 (9.9)
Anthracyclines 320 (42.4) 5 (17.2) 315 (43.4)
Anthracyclines and taxanes 122 (16.2) 12 (41.4) 110 (15.2)
CHOP-like 53 (7.0) 3 (10.3) 50 (6.9)
Platinum-based 108 (14.3) 0 108 (14.9)
Methotrexate 1 (0.4) 1 (3.4) 0
Leukemia regimen 36 (4.8) 6 (20.7) 30 (4.1)
Temozolomide 3 (0.4) 1 (3.4) 2 (0.3)
Other 39 (5.2) 0 39 (5.4)










0-3.9 10 (1.3) 10 (34.5) 0
4-9.9 9 (1.3) 9 (31.0) 0
10-13.9 42 (5.4) 10 (34.5) 32 (4.4)
14-27.9 535 (70.8) 0 535 (73.7)
28-40.0 159 (21.1) 0 159 (21.9)
Other medication
during pregnancy
G-CSF 77 (10.2) 8 (27.6) 69 (9.5)
Tamoxifen 2 (0.3) 2 (6.9) 0
Trastuzumab 3 (0.4) 0 3 (0.4)
Rituximab 41 (5.4) 0 41 (5.6)
Imatinib 1 (0.1) 0 1 (0.1)
GnRH analogue 1 (0.1) 1 (3.4) 0
Isotretinoine 1 (0.1) 1 (3.4) 0
Mercaptopurin 12 (1.6) 12 (41.4) 0
Pregnancy outcome
Live birth 745 (98.7) 23 (79.3) 722 (99.4)
Stillbirth 4 (0.5) 0 4 (0.6)
Miscarriage 3 (0.4) 3 (10.3) 0
Termination 3 (0.4) 3 (10.3) 0
Singleton/multiple pregnancy
Singleton 731 (96.8) 21 (72.4) 710 (97.8)
Multiple 18 (2.4) 2 (6.9) 16 (2.2)
Gestational age at delivery,









<28 9 (1.2) 0 9 (1.2)
28.0-31.9 38 (5.1) 3 (13.0) 35 (4.8)
32.0-33.9 71 (9.5) 2 (8.7) 69 (9.6)
34.0-36.9 277 (37.2) 3 (13.0) 274 (38.0)
≥37.0 35(47.0) 15 (65.2) 335 (46.4)
Congenital malformations (n = 749)a
None 708 (94.5) 17 (73.9) 691 (95.2)
Minor 14 (1.9) 1 (4.3) 13 (1.8)
Major 27 (3.6) 5 (21.7) 22 (3.0)
Abbreviations: ART, assisted reproductive technology;
ABVD, doxorubicin, bleomycin, vinblastine,
dacarbazine; CHOP, cyclophosphamide, doxorubicin,
vincristine; G-CSF, granulocyte colony-stimulating
factor; GnRH, gonadotropin-releasing hormone; IQR,
interquartile range.
a Comparison between occurrence of minor and major
malformations between groups by Fisher exact:
P < .01 for major malformations and P = .36 for minor
malformations.
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<4 4-9 10-11 12-13 14-15 16-17 18-19 20-21 22-23 24-25 26-27 28-29 30-31 >32
None Minor Major
Congenital anomalies
The dotted line indicates 7%, the maximum
percentage of congenital malformations (minor and
major) according to gestational age at initiation of
chemotherapy, from 12 weeks onward.




(n = 29) Chemotherapy regimen Congenital malformation
Initiation at <4 wk GA (n = 10)
Miscarriage 2 NR NA
Termination 2 Polychemotherapy (n = 1) for AML
NA
MTX (n = 1) for AML
Live birth, no
malformations
3 CHOP (n = 1)
NATemozolomide (n = 1)
MTX (n = 1)
Live birth, with
malformations
3 Temozolomide (n = 1) Microcephalya
TAC (G-CSF) (n = 1) Limb abnormalities (bilateral
III-IV syndactyly of hands and
feet, and a hypoplasia of the
right thumb)a
TAC (tamoxifen + G-CSF + RT breast)
(n = 1)
VSD and unilateral kidney
agenesiaa
Initiation at 4-9 wk GA (n = 9)
Miscarriage 1 Polychemotherapy (n = 1) for AML NA
Termination 1 Polychemotherapy (n = 1) for CLL NA
Live birth, no
malformations
5 Ara-C (n = 1)
NAFEC (n = 1)
AC (n = 3)
Live birth, with
malformations
2 CHOP (n = 1) Epstein anomaly and
dextrocardiaa
FEC (tamoxifen +GnRH agonist) (n = 1) Limb abnormalitiesa
Initiation at 10-11 wk GA (n = 10)
Miscarriage 0 NA NA
Termination 0 NA NA
Live birth, no
malformations
9 ABVD (n = 1)
NA
AC (n = 5)
AC (G-CSF) (n = 1)
EC (G-CSF) (n = 2)
Live birth, with
malformations
1 AC (n = 1) Plagiocephaly
Abbreviations: ABVD, doxorubicin, bleomycin,
vinblastine, dacarbazine; AC, doxorubicin,
cyclophosphamide; AML, acute myeloid leukemia;
Ara-C, cytarabine; CHOP, cyclophosphamide,
doxorubicin, vincristine; CLL, chronic lymphocytic
leukemia; EC, epirubicin; F, 5-flourouracil,
cyclophosphamide; GA, gestational age; G-CSF,
granulocyte colony-stimulating factor; GnRH,
gonadotropin-releasing hormone; MTX, methotrexate;
NA, not applicable; NR, not reported; RT, radiation
therapy; TAC, doxorubicin, cyclophosphamide,
docetaxel; VSD, ventricular sepal defect.
a Major congenital malformation according
to EUROCAT.
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We focused on structural malformations detected prenatally or at birth. Adverse effects and
malformations can become apparent after birth as the eyes, genitalia, hematopoietic, and central
nervous system continue to develop during childhood.1 Nevertheless, after birth, other confounders
(eg, infections, medication use, environmental factors) play a role. A cohort study on 225 pregnant
patients receiving chemotherapy after 12 weeks of pregnancy focused on structural birth anomalies
diagnosed up to 5 years after birth and revealed an increased risk when chemotherapy was
administered between 12 and 17 weeks of gestation.9 The causality of chemotherapy was unclear, as
reported malformations were very heterogeneous (eg, pyloric stenosis, plagiocephaly, spina bifida)
and could be also explained by other factors (eg, genetics, prematurity, folate deficiency).
Functional anomalies, sometimes subtle, might appear in early childhood or later. Among
pediatric patients who were directly exposed to chemotherapy, anthracyclines are notorious for
cardiotoxic effects, whereas platinum derivatives are associated with early ototoxicity.10,11 Another
concern is the evolution of neurocognitive functions in the long term, since the central nervous
system continues to develop during the second and third trimester of pregnancy. Postnatal exposure
to chemotherapeutics has been associated with long-term genotoxic effects, such as a secondary
malignant neoplasm and premature aging.12,13 To date, cohort studies on children exposed to
chemotherapy prenatally report overall reassuring results, mostly based on general health, cardiac
evaluation, and cognitive development until the age 6 years.14 Additionally, these clinical studies did
not report on genotoxic effects after prenatal chemotherapy. Since the administration of
chemotherapy in cancer treatment concerns combinatorial regimens of multiple chemotherapeutic
agents and could differ per patient or hospital, reported results cannot provide information about the
safety or risks of individual chemotherapeutic agents. Therefore, more research regarding genetic
damage and developmental aspects with subsequent long-term follow-up is planned.
Data on the risks of congenital malformations are indispensable for clinicians and patients when
considering chemotherapy during pregnancy. Based on our findings, we suggest that when cancer is
diagnosed in early pregnancy, chemotherapy can be initiated from 12 weeks onward. Therefore,
accurate ultrasonographic dating is crucial. The introduction of a 1-week safety period could be
considered to further minimize the risk of chemotherapy-induced congenital malformations.
However, no rationale exists to delay the start of chemotherapy beyond 14 weeks of gestation, as
recommended previously.2 If a patient desires certainty on risk of chromosomal anomalies, an
amniocentesis for karyotyping and microarray could be offered, since noninvasive prenatal testing is
not conclusive in patients with cancer owing to tumor cell-free DNA interference.15
Limitations
This study has some limitations. One important limitation of the INCIP cohort is that it is prone to
selection bias, and data cannot be interpreted as population-based incidences. Based on this study,
the absolute occurrence of anomalies after chemotherapy was impossible to assess, and minor
anomalies are likely underreported. Additionally, early miscarriages and terminations of pregnancy
are likely to be underrepresented in the INCIP registry, and with the substantial evolution of
ultrasonographic imaging and improved prenatal diagnosis of congenital malformations over the
years, more pregnancies might have been terminated. Furthermore, the use of multiple medications
and treatment regimens in cancer treatment complicates the interpretation of results.
Conclusions
These findings suggest that chemotherapy during the first 12 weeks of pregnancy was associated
with increased risk for congenital malformations in the fetus. If an aggressive cancer diagnosis during
early pregnancy does not allow treatment delay, parents should be counseled on fetal risks of
malformations. If a patient incidentally becomes pregnant while receiving chemotherapy, prenatal
counselling should include the risks of both short- and long-term adverse outcomes. Adequate
anticonception and routine pregnancy tests should be offered to fertile women with cancer.
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